| The prevalence and correlates of childhood trauma in patients with early psychosis M Duhig, S Patterson, M Connell, S Foley, C Capra, F Dark, A Gordon, ... Australian & New Zealand Journal of Psychiatry 49 (7), 651-659, 2015 | 150 | 2015 |
| Modifiable risk factors for schizophrenia and autism—Shared risk factors impacting on brain development J Hamlyn, M Duhig, J McGrath, J Scott Neurobiology of disease 53, 3-9, 2013 | 88 | 2013 |
| Implementing music therapy on an adolescent inpatient unit: A mixed-methods evaluation of acceptability, experience of participation and perceived impact S Patterson, M Duhig, C Darbyshire, R Counsel, N Higgins, I Williams Australasian Psychiatry 23 (5), 556-560, 2015 | 38 | 2015 |
| The association between maltreatment in childhood and pre-pregnancy obesity in women attending an antenatal clinic in Australia K Hollingsworth, L Callaway, M Duhig, S Matheson, J Scott PLoS One 7 (12), e51868, 2012 | 38 | 2012 |
| A pilot study of the effects of an Australian centre-based early intervention program for children with autism J Paynter, J Scott, W Beamish, M Duhig, H Heussler The Open Pediatric Medicine Journal 6 (1), 2012 | 38 | 2012 |
| Understanding readmission to psychiatric hospital in Australia from the service users’ perspective: a qualitative study M Duhig, I Gunasekara, S Patterson Health & social care in the community 25 (1), 75-82, 2017 | 36 | 2017 |
| Successful recruitment to a study of first-episode psychosis by clinicians: a qualitative account of outcomes and influences on process S Patterson, M Duhig, M Connell, J Scott Journal of Mental Health 23 (5), 225-230, 2014 | 13 | 2014 |
| National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story S Hollingworth, M Duhig, W Hall, J Scott Australasian Psychiatry 21 (5), 442-445, 2013 | 12 | 2013 |
| Environmental contributions to autism: explaining the rise in incidence of autistic spectrum disorders J Scott, M Duhig, J Hamlyn, R Norman Journal of Environmental Immunology and Toxicology 1 (2), 75-79, 2014 | 9 | 2014 |
| Efficacy of risperidone in children with disruptive behavioural disorders MJ Duhig, S Saha, JG Scott Journal of Paediatrics and Child Health 49 (1), 19-26, 2013 | 6 | 2013 |
| & Scott, J.(2015). The prevalence and correlates of childhood trauma in patients with early psychosis M Duhig, S Patterson, M Connell, S Foley, C Capra, F Dark Australian and New Zealand Journal of Psychiatry 49 (7), 0 | 4 | |
| Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT … H Heussler, M Duhig, T Hurst, C O’Neill, D Gutterman, JM Palumbo, ... Adolesc. Psychiatry 12, 24, 2020 | 2 | 2020 |
| Longer-term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder: An Open-label Phase 2 Study (BRIGHT [ZYN2 … JM Palumbo, H Heussler, MJ Duhig, T Hurst, C O’Neill, T Sebree Pediatrics 149 (1 Meeting Abstracts February 2022), 264-264, 2022 | 1 | 2022 |
| An Open-Label Trial Assessing Short-and Long-Term Tolerability and Efficacy of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11. 2 … H Heussler, M Duhig, J Cohen, C Buchanan, C O'Neill, S O'Quinn JOURNAL OF INTELLECTUAL DISABILITY RESEARCH 67 (9), 808-809, 2023 | | 2023 |
| Longer-Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder: an Open-Label Phase 2 Study (BRIGHT [ZYN2 … H Heussler, M Duhig, T Hurst, C O'Neill, D Gutterman, J Palumbo JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS 43 (2), E142-E142, 2022 | | 2022 |
| Medicinal cannabis for children with cancer: The MINI trial A Herbert, HS Heussler, H Irving, M Mitchell, I McGregor, G Wallace, ... Supportive Care in Cancer 30 (Suppl 1), S138, 2022 | | 2022 |
| LONGER-TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2 … J Palumbo, H Heussler, M Duhig, T Hurst, C O'Neill, T Sebree Journal of the American Academy of Child & Adolescent Psychiatry 60 (10), S258, 2021 | | 2021 |
| [Bright (ZYN2-CL-030)] Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study DM Helen Heussler FRACP, M Duhig, T Hurst, C O'Neill, D Gutterman, ... 2020 Virtual Meeting, 2020 | | 2020 |
| [BRIGHT (ZYN2-CL-030)] TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY H Heussler, M Duhig, T Hurst, C O'Neill, D Gutterman, JM Palumbo Journal of the American Academy of Child & Adolescent Psychiatry 59 (10 …, 2020 | | 2020 |
| Phase 2 BRIGHT (An open-label tolerability and efficacy study of ZYN002 administered as a transdermal gel to children and adolescents with autism spectrum disorder): Baseline … H Heussler, M Duhig, T Hurst, C O'Neill, W Agnese, JM Palumbo NEUROTHERAPEUTICS 17 (3), 1321-1322, 2020 | | 2020 |
Prof James G. ScottQIMR Berghofer Medical Research InstituteVerified email at health.qld.gov.au
